The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC).
 
Benjamin L. Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Merck; Peloton Therapeutics; Pfizer; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Melissa Plets
No Relationships to Disclose
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Yasser Ged
Consulting or Advisory Role - AVEO; BostonGene; Bristol Myers Squibb; Eisai; Exelixis; Targeted Oncology; Targeted Oncology
 
Catherine Tangen
No Relationships to Disclose
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Merck Serono; Pfizer; Sanofi/Aventis
Speakers' Bureau - Bayer; Exelixis; Pfizer
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Seth P. Lerner
Stock and Other Ownership Interests - Aura Biosciences; C2i genomics
Honoraria - Grand Rounds in Urology; UroToday
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb Foundation/Janssen; C2i Genomics; Ferring; Pfizer/EMD Serono; Protara Therapeutics; Stimit; Vaxiion; Verity Pharmaceuticals
Research Funding - Endo Pharmaceuticals; FKD Therapies; Japan BCG Laboratory; QED Therapeutics; Roche/Genentech; Vaxiion; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier
Other Relationship - Bladder Cancer Journal; UpToDate
 
Ian M. Thompson
Leadership - H-E-B (grocery store chain)
Consulting or Advisory Role - Magforce
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme